Pfizer

4Q Revenues: $17.6 billion (-1%) 

4Q Loss: $1.6 billion (earnings were $411 million 4Q25) 

FY Revenues: $62.6 billion (-2%) 

FY Earnings: $7.8 billion (-3%) 

Comments: Revenue in the quarter reflects an operational decrease primarily driven by a year-over-year decline in COVID-19 products, partially offset by an increase in revenues for Abrysvo, Oncology biosimilars, Eliquis, the Prevnar family, the Vyndaqel family, and several other products. Excluding declines for Comirnaty and Paxlovid, revenues for the quarter grew 9% operationally. Pfizer CentreOne sales were $409 million in the quarter, up 26%.

Eliquis sales were $2.0 billion in the quarter, up 10%. Prevnar family sales were $1.7 billion, up 10%. Vyndaqel family sales were up 9% to $1.7 billion. Ibrance sales were down 5% to $1.0 billion. Xtandi sales were $592 million up 5%. Abrysvo sales were $481 million in the quarter, up 143%.

The unfavorable period-over-period change in Other (income)/deductions—net of $2.2 billion for the fourth quarter of 2025, was driven primarily by higher intangible asset impairment charges, lower net gains on equity securities and the non-recurrence of gains on the partial sale of previous investment in Haleon plc equity in the fourth quarter of 2024.